Advertisement

Early Pregnancy Support: Evidence-Based Management

  • Valarmathy KandavelEmail author
  • Siobhan Quenby
Chapter

Abstract

Early pregnancy is traditionally defined as the first trimester of pregnancy, which is up to 13 completed weeks of pregnancy. This is a time of rapid growth of the embryo to the stage of the fetus and completion of organogenesis. This is also considered the most anticipated and vulnerable stage of pregnancy, with 1 in 6 pregnancies ending in a miscarriage. This chapter outlines the evidence around the current pharmacological, supportive and life style advices that couples frequently ask about. Early pregnancy support helps the woman and the couple transition into the remainder of pregnancy with confidence and positive emotions. This plays a key role in the psychological and pregnancy outcomes. Pharmacological interventions help improve the pregnancy outcomes but only in limited number of associated disorders. The policy of “tender loving care” however has universal applications for all pregnant patients.

Keywords

Early pregnancy Support Lifestyle choices Safety Reassurance Ultrasound Scan Supportive care Advice Evidence 

References

  1. 1.
    Musters AM, Taminiau-Bloem EF, van den Boogaard E, van der Veen F, Goddijn M. Supportive care for women with unexplained recurrent miscarriage: patient’s perspectives. Hum Reprod. 2011;26(4):873–7.CrossRefPubMedGoogle Scholar
  2. 2.
    Li TC. Recurrent miscarriage: principles of management. Hum Reprod. 1998;13(2):478–82.CrossRefPubMedGoogle Scholar
  3. 3.
    Van den Berg MM, Vissenberg R, Goddijn M. Recurrent miscarriage clinics. Obstet Gynecol Clin N Am. 2014;41:145–55.CrossRefGoogle Scholar
  4. 4.
    Nikcevic DAV, Tunkel SA, Nicolaides KH. psychological outcomes following missed abortions and provision of follow-up care. Ultrasound Obstet Gynecol. 1998;11(2):123–8.CrossRefPubMedGoogle Scholar
  5. 5.
    Habayeb OM, Konje JC. The one-stop recurrent miscarriage clinic: an evaluation of its effectiveness and outcome. Hum Reprod. 2004;19(12):2952–8.CrossRefPubMedGoogle Scholar
  6. 6.
    Stray-Pedersen B, Stray-Pedersen A. Etiologic factors and subsequent reproductive performance in 195 couples with a prior history of habitual abortion. Am J Obstet Gynecol. 1984;148.Google Scholar
  7. 7.
    Clifford K, Rai R, Regan L. Future pregnancy outcome in unexplained recurrent first trimester miscarriage. Hum Reprod. 1997;12(2):387–9.CrossRefPubMedGoogle Scholar
  8. 8.
    Coleman T, Chamberlain C, Davey M, Cooper SE, Leonardi-Bee J. Pharmacological interventions for promoting smoking cessation during pregnancy. Cochrane Database Syst Rev. 2015;(12):CD010078.Google Scholar
  9. 9.
    Cooper S, Lewis S, Thornton JG, Marlow N, Watts K, Britton J, Grainge MJ, Taggar J, Essex H, Parrott S, Dickinson A, Whitemore R, Coleman T. The SNAP trial: a randomised placebo-controlled trial of nicotine replacement therapy in pregnancy—clinical effectiveness and safety until 2 years after delivery, with economic evaluation; Smoking, Nicotine and Pregnancy Trial Team. Health Technol Assess. 2014;18(54):1–128.CrossRefGoogle Scholar
  10. 10.
    Britton J, McNeill A, Hopkinson N. Nicotine without smoke: putting electronic cigarettes in context. BMJ. 2016;353:i1745.CrossRefPubMedGoogle Scholar
  11. 11.
    Stade BC, Bailey C, Dzendoletas D, Sgro M, Dowswell T, Bennett D. Psychological and/or educational interventions for reducing alcohol consumption in pregnant women and women planning pregnancy. Cochrane Database Syst Rev. 2009;(2):CD004228.Google Scholar
  12. 12.
    Department of Health. Health risks from alcohol: new guidelines. 8 Jan 2016.Google Scholar
  13. 13.
    Kramer MS, McDonald SW. Aerobic exercise for women during pregnancy. Cochrane Database Syst Rev. 2006;(3):CD000180.Google Scholar
  14. 14.
    Lassi ZS, Salam RA, Haider BA, Bhutta ZA. Folic acid supplementation during pregnancy for maternal health and pregnancy outcomes. Cochrane Database Syst Rev. 2013;(3):CD006896.Google Scholar
  15. 15.
    De-Regil L, Peña-Rosas J, Fernández-Gaxiola AC, Rayco-Solon P. Effects and safety of periconceptional oral folate supplementation for preventing birth defects. Cochrane Database Syst Rev. 2015;(12):CD007950.Google Scholar
  16. 16.
    De-Regil L, Palacios C, Lombardo LK, Peña-Rosas J. Vitamin D supplementation for women during pregnancy. Cochrane Database Syst Rev. 2016;(1):CD008873.Google Scholar
  17. 17.
    Martin TR, Bracken MB. The association between low birth weight and caffeine consumption during pregnancy. Am J Epidemiol. 1987;126(5):813–21.PubMedGoogle Scholar
  18. 18.
    Jahanfar S, Jaafar S. Effects of restricted caffeine intake by mother on fetal, neonatal and pregnancy outcomes. Cochrane Database Syst Rev. 2015;(6):CD006965.Google Scholar
  19. 19.
    Wing Sze E, Hung Yu Ng E. Acupuncture in reproductive medicine. Womens Health. 2010;6(4):551–63.Google Scholar
  20. 20.
    Furber CM, McGowan L, Bower P, Kontopantelis E, Quenby S, Lavender T. Antenatal interventions for reducing weight in obese women for improving pregnancy outcome. Cochrane Database Syst Rev. 2013;(1):CD009334.Google Scholar
  21. 21.
    Chiswick C, Reynolds RM, Denison F, et al. Effect of metformin on maternal and fetal outcomes in obese pregnant women (EMPOWaR): a randomised, double-blind, placebo-controlled trial. Lancet Diabet Endocrinol. 2015;3(10):778–86.CrossRefGoogle Scholar
  22. 22.
    Syngelaki A, Nicolaides KH, Balani J, Hyer S, Akolekar R, Kotecha R, Pastides A, Shehata H. Metformin versus placebo in obese pregnant women without diabetes mellitus. N Engl J Med. 2016;374:434–43.CrossRefPubMedGoogle Scholar
  23. 23.
    van der Linden M, Buckingham K, Farquhar C, Kremer JAM, Metwally M. Luteal phase support for assisted reproduction cycles. Cochrane Database Syst Rev. 2015;(7):CD009154.Google Scholar
  24. 24.
    Coomarasamy A, Williams H, Truchanowicz E, Seed PT, Small R, Quenby S, Gupta P, Dawood F, Koot Y, Atik RB, Bloemenkamp KWM, Brady R, Briley AL, Cavallaro R, Cheong YC, Chu JJ, Eapen A, Ewies A, Hoek A, Kaaijk EM, Koks CAM, Li T-C, MacLean M, Mol BW, Moore J, Ross JA, Sharpe L, Stewart J, Vaithilingam N, Farquharson RG, Kilby MD, Khalaf Y, Goddijn M, Regan L, Rai R. A randomized trial of progesterone in women with recurrent miscarriages. N Engl J Med. 2015;373:2141–8.CrossRefPubMedGoogle Scholar
  25. 25.
    Haas DM, Ramsey PS. Progestogen for preventing miscarriage. Cochrane Database Syst Rev. 2013;(10):CD003511.Google Scholar
  26. 26.
    Wahabi HA, Fayed AA, Esmaeil SA, Al Zeidan RA. Progestogen for treating threatened miscarriage. Cochrane Database Syst Rev. 2011;(12):CD005943.Google Scholar
  27. 27.
    The PRISM study is a large randomised, double-blind and placebo-controlled multi-centre trial of the effectiveness of progesterone in reducing miscarriage rates in women with early pregnancy bleeding. The PRISM trial is funded solely by NIHR-HTA (UK). http://www.birmingham.ac.uk/research/activity/mds/trials/bctu.
  28. 28.
    de Jong PG, Kaandorp S, Di Nisio M, Goddijn M, Middeldorp S. Aspirin and/or heparin for women with unexplained recurrent miscarriage with or without inherited thrombophilia. Cochrane Database Syst Rev. 2014;(7):CD004734.Google Scholar
  29. 29.
    de Jong PG, Quenby S, Bloemenkamp KWM, Braams-Lisman BAM, de Bruin JP, Coomarasamy A, David M, DeSancho MT, van der Heijden OWH, Hoek A, Hutten BA, Jochmans K, Koks CAM, Kuchenbecker WH, Mol BWJ, Torrance HL, Scheepers HCJ, Stephenson MD, Verhoeve HR, Visser JV, de Vries JIP, Goddijn M, Middeldorp S. ALIFE2 study: low-molecular-weight heparin for women with recurrent miscarriage and inherited thrombophilia – study protocol for a randomized controlled trial. Trials. 2015;16:208.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Akhtar MA, Sur S, Raine-Fenning N, Jayaprakasan K, Thornton JG, Quenby S. Heparin for assisted reproduction. Cochrane Database Syst Rev. 2013;(8):CD009452.Google Scholar
  31. 31.
    Check JH. The use of heparin for preventing miscarriage. Am J Reprod Immunol. 2012;67(4):326–33.CrossRefPubMedGoogle Scholar
  32. 32.
    Hypertension in pregnancy: diagnosis and management NICE guidelines [CG107]. Published date: Aug 2010. Last updated: Jan 2011.Google Scholar
  33. 33.
    Kaandorp SP, Goddijn M, van der Post JA, Hutten BA, Verhoeve HR, Hamulyák K, Mol BW, Folkeringa N, Nahuis M, Papatsonis DN, Büller HR, van der Veen F, Middeldorp S. Aspirin plus heparin or aspirin alone in women with recurrent miscarriage. N Engl J Med. 2010;362(17):1586–96.CrossRefPubMedGoogle Scholar
  34. 34.
    Tang AW, Alfirevic Z, Turner MA, Drury JA, Small R, Quenby S. A feasibility trial of screening women with idiopathic recurrent miscarriage for high uterine natural killer cell density and randomizing to prednisolone or placebo when pregnant. Hum Reprod. 2013;28(7):1743–52.CrossRefPubMedGoogle Scholar
  35. 35.
    Wong LF, Porter T, Scott JR. Immunotherapy for recurrent miscarriage. Cochrane Database Syst Rev. 2014;(10):CD000112.Google Scholar
  36. 36.
    Zeyneloglu HB, Onalan G. Remedies for recurrent implantation failure. Semin Reprod Med. 2014;32(4):297–305.CrossRefPubMedGoogle Scholar
  37. 37.
    Quenby S, Farquharson RG. Human chorionic gonadotropin supplementation in recurring pregnancy loss: a controlled trial. Fertility Sterility. 1994;62(4):708–10.CrossRefPubMedGoogle Scholar
  38. 38.
    Morley LC, Simpson N, Tang T. Human chorionic gonadotrophin (hCG) for preventing miscarriage. Cochrane Database Syst Rev. 2013;(1):CD008611.Google Scholar
  39. 39.
    Devaseelan P, Fogarty PP, Regan L. Human chorionic gonadotrophin for threatened miscarriage. Cochrane Database Syst Rev. 2010;(5):CD007422.Google Scholar
  40. 40.
    Rai L, Regan L. Recurrent miscarriage. Lancet. 2006;601–11.Google Scholar
  41. 41.
    American Society for Reproductive Medicine. Evaluation and treatment of recurrent pregnancy loss: a committee opinion. Fertil Steril. 2012;98:1103–11.CrossRefGoogle Scholar
  42. 42.
    Kataoka K, Tomiya Y, Sakamoto A, Kamada Y, Hiramatsu Y, Nakatsuka M. Altered autonomic nervous system activity in women with unexplained recurrent pregnancy loss. J Obstet Gynaecol Res. 2015;41(6):912–8.CrossRefPubMedGoogle Scholar
  43. 43.
    Kolte AM, Olsen LR, Mikkelsen EM, Christiansen OB, Nielsen HS. Depression and emotional stress is highly prevalent among women with recurrent pregnancy loss. Hum Reprod. 2015;4:777–82.CrossRefGoogle Scholar
  44. 44.
    Kolte AM, Olsen LR, Christiansen OB, Nielsen HS. Stress and depression at referral do not entail a lower chance of live birth/ongoing pregnancy for women with recurrent pregnancy loss. Copenhagen University Hospital Rigshospitalet, Recurrent Pregnancy Loss Unit Fertility Clinic Section 4071, Copenhagen, ESHRE 2015 abstract O-168.Google Scholar
  45. 45.
    Tang AW, Quenby S. Recent thoughts on management and prevention of recurrent early pregnancy loss. Curr Opin Obstet Gynecol. 2010;22(6):446–51.CrossRefPubMedGoogle Scholar
  46. 46.
    Bailey S, Bailey C, Boivin J, Cheong Y, Reading I, Macklon N. A feasibility study for a randomised controlled trial of the positive reappraisal coping intervention, a novel supportive technique for recurrent miscarriage. BMJ Open. 2015;5, e007322.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2017

Authors and Affiliations

  1. 1.Department of Obstetrics and GynaecologyUniversity Hospitals of Coventry and Warwickshire NHS TrustCoventryUK
  2. 2.Department of Reproductive HealthUniversity of Warwick, University Hospitals Coventry and Warwickshire NHS TrustCoventryUK

Personalised recommendations